These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Loss of 1p, 19q, and 10q heterozygosity prospectively predicts prognosis of oligodendroglial tumors--towards individualized tumor treatment? Ramirez C; Bowman C; Maurage CA; Dubois F; Blond S; Porchet N; Escande F Neuro Oncol; 2010 May; 12(5):490-9. PubMed ID: 20156805 [TBL] [Abstract][Full Text] [Related]
3. Prognostic stratification of patients with anaplastic gliomas according to genetic profile. Dehais C; Laigle-Donadey F; Marie Y; Kujas M; Lejeune J; Benouaich-Amiel A; Pedretti M; Polivka M; Xuan KH; Thillet J; Delattre JY; Sanson M Cancer; 2006 Oct; 107(8):1891-7. PubMed ID: 16986124 [TBL] [Abstract][Full Text] [Related]
4. Loss of heterozygosity on chromosomes 10q, 9p, 17p and 13q in malays with malignant glioma. Zainuddin N; Jaafart H; Isa MN; Abdullah JM Neurol Res; 2004 Jan; 26(1):88-92. PubMed ID: 14977064 [TBL] [Abstract][Full Text] [Related]
5. Contribution of 1p, 19q, 9p and 10q Automated Analysis by FISH to the Diagnosis and Prognosis of Oligodendroglial Tumors According to WHO 2016 Guidelines. Michaud K; de Tayrac M; D'Astous M; Duval C; Paquet C; Samassekou O; Gould PV; Saikali S PLoS One; 2016; 11(12):e0168728. PubMed ID: 28030632 [TBL] [Abstract][Full Text] [Related]
6. Loss of heterozygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: relationship to outcome and chemosensitivity. Thiessen B; Maguire JA; McNeil K; Huntsman D; Martin MA; Horsman D J Neurooncol; 2003 Sep; 64(3):271-8. PubMed ID: 14558604 [TBL] [Abstract][Full Text] [Related]
7. Loss of 22q chromosome is related to glioma progression and loss of 10q. Laigle-Donadey F; Crinière E; Benouaich A; Lesueur E; Mokhtari K; Hoang-Xuan K; Sanson M J Neurooncol; 2006 Feb; 76(3):265-8. PubMed ID: 16283437 [TBL] [Abstract][Full Text] [Related]
8. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression. Hoang-Xuan K; He J; Huguet S; Mokhtari K; Marie Y; Kujas M; Leuraud P; Capelle L; Delattre JY; Poirier J; Broët P; Sanson M Neurology; 2001 Oct; 57(7):1278-81. PubMed ID: 11591848 [TBL] [Abstract][Full Text] [Related]
9. Analysis of 1p, 19q, 9p, and 10q as prognostic markers for high-grade astrocytomas using fluorescence in situ hybridization on tissue microarrays from Radiation Therapy Oncology Group trials. Brat DJ; Seiferheld WF; Perry A; Hammond EH; Murray KJ; Schulsinger AR; Mehta MP; Curran WJ; Neuro Oncol; 2004 Apr; 6(2):96-103. PubMed ID: 15134623 [TBL] [Abstract][Full Text] [Related]
10. Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas. Iwamoto FM; Nicolardi L; Demopoulos A; Barbashina V; Salazar P; Rosenblum M; Hormigo A J Neurooncol; 2008 Jul; 88(3):293-8. PubMed ID: 18345516 [TBL] [Abstract][Full Text] [Related]
11. Gliomas: association of histology and molecular genetic analysis of chromosomes 1p, 10q, and 19q. Gresner SM; Rieske P; Wozniak K; Piaskowski S; Jaskolski DJ; Skowronski W; Sikorska B; Papierz W; Liberski PP Acta Neurobiol Exp (Wars); 2007; 67(2):103-12. PubMed ID: 17691218 [TBL] [Abstract][Full Text] [Related]
12. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. Cairncross JG; Ueki K; Zlatescu MC; Lisle DK; Finkelstein DM; Hammond RR; Silver JS; Stark PC; Macdonald DR; Ino Y; Ramsay DA; Louis DN J Natl Cancer Inst; 1998 Oct; 90(19):1473-9. PubMed ID: 9776413 [TBL] [Abstract][Full Text] [Related]
13. Loss of heterozygosity 1p/19q and survival in glioma: a meta-analysis. Zhao J; Ma W; Zhao H Neuro Oncol; 2014 Jan; 16(1):103-12. PubMed ID: 24311641 [TBL] [Abstract][Full Text] [Related]
14. Molecular analysis of chromosome 1, 10 and 19 abnormalities in human oligodendroglial tumors: relationship between frequency of LOH grade, age and gender. Gresner SM; Rieske P; Wozniak K; Piaskowski S; Jaskolski DJ; Skowronski W; Golanska E; Sikorska B; Liberski PP Clin Neuropathol; 2006; 25(1):18-24. PubMed ID: 16465770 [TBL] [Abstract][Full Text] [Related]
15. Association between fluorine-18-labeled fluorodeoxyglucose uptake and 1p and 19q loss of heterozygosity in World Health Organization Grade II gliomas. Stockhammer F; Thomale UW; Plotkin M; Hartmann C; Von Deimling A J Neurosurg; 2007 Apr; 106(4):633-7. PubMed ID: 17432715 [TBL] [Abstract][Full Text] [Related]
16. Chromosomal alterations in oligodendroglial tumours over multiple surgeries: is tumour progression associated with change in 1p/19q status? Campbell BA; Horsman DE; Maguire J; Young S; Curman D; Ma R; Thiessen B J Neurooncol; 2008 Aug; 89(1):37-45. PubMed ID: 18458822 [TBL] [Abstract][Full Text] [Related]
17. Chromosome 1p loss: a favorable prognostic factor in low-grade gliomas. Kujas M; Lejeune J; Benouaich-Amiel A; Crinière E; Laigle-Donadey F; Marie Y; Mokhtari K; Polivka M; Bernier M; Chretien F; Couvelard A; Capelle L; Duffau H; Cornu P; Broët P; Thillet J; Carpentier AF; Sanson M; Hoang-Xuan K; Delattre JY Ann Neurol; 2005 Aug; 58(2):322-6. PubMed ID: 16049942 [TBL] [Abstract][Full Text] [Related]
18. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179 [TBL] [Abstract][Full Text] [Related]
19. Spatial and temporal evolution of distal 10q deletion, a prognostically unfavorable event in diffuse low-grade gliomas. van Thuijl HF; Scheinin I; Sie D; Alentorn A; van Essen HF; Cordes M; Fleischeuer R; Gijtenbeek AM; Beute G; van den Brink WA; Meijer GA; Havenith M; Idbaih A; Hoang-Xuan K; Mokhtari K; Verhaak RG; van der Valk P; van de Wiel MA; Heimans JJ; Aronica E; Reijneveld JC; Wesseling P; Ylstra B Genome Biol; 2014 Sep; 15(9):471. PubMed ID: 25245118 [TBL] [Abstract][Full Text] [Related]
20. Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. Fallon KB; Palmer CA; Roth KA; Nabors LB; Wang W; Carpenter M; Banerjee R; Forsyth P; Rich K; Perry A J Neuropathol Exp Neurol; 2004 Apr; 63(4):314-22. PubMed ID: 15099021 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]